Platform Technology to Enhance the Growth of Human Tissues In Vitro for Use in Biomedical Research and the Assessment of New Molecular Entities.

Lead Research Organisation: Durham University
Department Name: Chemistry


Testing the activity of molecules prior to human use is an essential step in the development of new drugs. Currently it is very challenging to evaluate compound activity and toxicity in human tissues directly due to the lack of appropriate test systems. In-vitro biomedical tests on human cells are possible using conventional two-dimensional (2D) cell culture techniques however the assays do not represent the true activity of molecules in real tissues. Three-dimensional (3D) cell culture radically improves cell structure and function enabling the formation of tissue-like constructs. This project involves the design of an innovative approach to combining 3D cell culture technology and the development of a novel bioreactor to maintain human tissues for biomedical assays. This is an interdisciplinary project drawing on expertise in biomedicine, chemistry and engineering. The mode of perfusion within the bioreactor will be informed by data from fluid dynamic simulations to control media flow. The bioreactor will incorporate oxygen control mechanisms. We hypothesise that our design will extend the viability of tissue models for chronic exposure studies and the testing new compounds. We will demonstrate its application of aged human skin models to examine the chronic effect of new senolytic molecules to enhance skin quality during ageing.

Planned Impact

The CDT has five primary beneficiaries:
The CDT cohort
Our students will receive an innovative training experience making them highly employable and equipping them with the necessary knowledge and skillset in science and enterprise to become future innovators and leaders. The potential for careers in the field is substantial and students graduating from the CDT will be sought after by employers. The Life Sciences Industrial strategy states that nearly half of businesses cite a shortage of graduates as an issue in their ability to recruit talent. Collectively, the industrial partners directly involved in the co-creation of the proposal have identified recruitment needs over the next decade that already significantly exceed the output of the CDT cohort.
Life science industries
The cohort will make a vital contribution to the UK life sciences industry, filling the skills gap in this vital part of the economy and providing a talented workforce, able to instantly focus on industry relevant challenges. Through co-creation, industrial partners have shaped the training of future employees. Additional experience in management and entrepreneurship, as well as peer-to-peer activities and the beginning of a professional network provided by the cohort programme will enable graduates to become future leaders. Through direct involvement in the CDT and an ongoing programme of dissemination, stakeholders will benefit from the research and continue to contribute to its evolution. Instrument manufacturers will gain new applications for their technologies, pharmaceutical and biotech companies will gain new opportunities for drug discovery projects through new insight into disease and new methods and techniques.
Health and Society
Research outputs will ultimately benefit healthcare providers and patients in relevant areas, such as cancer, ageing and infection. Pathways to such impact are provided by involvement of industrial partners specialising in translational research and enabling networks such as the Northern Health Science Alliance, the First for Pharma group and the NHS, who will all be partners. Moreover, graduates of the CDT will provide future healthcare solutions throughout their careers in pharmaceuticals, biotechnology, contract research industries and academia.
UK economy
The cohort will contribute to growth in the life sciences industry, providing innovations that will be the vehicle for economic growth. Nationally, the Life Sciences Industrial Strategy Health Advanced Research Programme seeks to create two entirely new industries in the field over the next ten years. Regionally, medicines research is a central tenet of the Northern Powerhouse Strategy. The CDT will create new opportunities for the local life sciences sector, Inspiration for these new industries will come from researchers with an insight into both molecular and life sciences as evidenced by notable successes in the recent past. For example, the advent of Antibody Drug Conjugates and Proteolysis Targeting Chimeras arose from interdisciplinary research in this area, predominantly in the USA and have led to significant wealth and job creation. Providing a cohort of insightful, innovative and entrepreneurial scientists will help to ensure the UK remains at the forefront of future developments, in line with the aim of the Industrial Strategy of building a country confident, outward looking and fit for the future.
Both host institutions will benefit hugely from hosting the CDT. The enhancement to the research culture provided by the presence of a diverse and international cohort of talented students will be beneficial to all researchers allied to the theme areas of the programme, who will also benefit from attending many of the scientific and networking events. The programme will further strengthen the existing scientific and cultural links between Newcastle and Durham and will provide a vehicle for new collaborative research.


10 25 50

Studentship Projects

Project Reference Relationship Related To Start End Student Name
EP/S022791/1 01/05/2019 31/10/2027
2449084 Studentship EP/S022791/1 01/01/2021 31/12/2024 Chantal Stenger